---
title: "Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300552154.md"
description: "Ascendiant Capital maintained a Buy rating on Aytu BioPharma with a $15 price target, implying a 581.8% upside from the September 29 close of $2.20. The firm cited strong fiscal Q4 results exceeding estimates and consensus, with revenue reaching $16.1 million (up 6% YoY). Additionally, the launch of EXXUA targets the $22 billion U.S. market for major depressive disorder, positioning the company for significant growth."
datetime: "2026-09-30T09:56:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300552154.md)
  - [en](https://longbridge.com/en/news/300552154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300552154.md)
generator: "portal-rs"
---

# Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target

Ascendiant Capital maintained their Buy rating on Aytu BioPharma's stock with a price target of $15.00.

The price target implies an upside of 581.8% from the Sep 29 close of $2.20.

**Key takeaways from the analyst note**

**Strong Financial Performance**: Aytu BioPharma recently reported fiscal Q4 results that exceeded both internal estimates and consensus, with a revenue of $16.1 million, marking a 6% year-over-year increase. This positive financial performance supports investor confidence in the company's growth trajectory.

**Significant Market Opportunity**: The launch of EXXUA is targeting the substantial $22 billion U.S. prescription market for major depressive disorder (MDD), addressing a critical need for effective treatments with fewer side effects. This positions Aytu BioPharma for strong future growth and potential market leadership.

Explore more price target data and ratings for Aytu BioPharma on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AYTU.US](https://longbridge.com/en/quote/AYTU.US.md)

## Related News & Research

- [AYTU: EXXUA launch drives growth in CNS therapeutics, with FY26 revenue at $66.4M](https://longbridge.com/en/news/299813775.md)
- [Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales](https://longbridge.com/en/news/299809035.md)
- [Apple Inc. $AAPL Stock Bought by GTS Securities LLC](https://longbridge.com/en/news/300764812.md)
- [Seagate vs. Western Digital: One Stock Is a Buy After Today's Drop, but the Other Has More Upside, According to Goldman Sachs](https://longbridge.com/en/news/300813818.md)
- [Why Nvidia Stock Is Rising Today and Why Morgan Stanley Reinstates NVDA as a "Top Pick"](https://longbridge.com/en/news/300784037.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**